[New agents against atherosclerosis tested. Alarming findings, ACAT inhibitors seem to have proatherogenic effects].
Wiklund
Olov
O
Wallenberglaboratoriet, avdelningen för metabolism och kardiovaskulär forskning, Sahlgrenska akademin, Göteborgs universitet. wiklund@wlab.gu.se
D000081:Acetamides; D000085:Acetates / Q000009:adverse effects; D000818:Animals; D050197:Atherosclerosis / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D007210:Indoleacetic Acids / Q000009:adverse effects; D012307:Risk Factors; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors; D013449:Sulfonamides; D013451:Sulfonic Acids / Q000009:adverse effects; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
D000081:Acetamides; D000085:Acetates; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007210:Indoleacetic Acids; D013449:Sulfonamides; D013451:Sulfonic Acids; C423185:avasimibe; C509302:pactimibe; D002785:Sterol O-Acyltransferase